EUVIMEDEUVIMED entdecken
Fallbericht

Acquired von Willebrand Syndrome Associated with a Smoldering Multiple Myeloma, Successfully Treated by Daratumumab, Lenalidomide, and Dexamethasone

Michael Iarossi, Marie-Christiane Madeleine Vekemans, Nicolas Weynants, Cedric Hermans

Acta Haematologica · 2024

DOI: 10.1159/000536650 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Acta Haematologica, 2024. Verfasst von Michael Iarossi und 3 weiteren Autor:innen. Beteiligte Einrichtung: Division of Haematology, Haemostasis and Thrombosis Unit, Saint-Luc University Hospital, Université catholique de Louvain (UCLouvain), Brussels, Belg…. Hauptthemen laut MEDLINE: Lenalidomide, Dexamethasone, von Willebrand Diseases, Antibodies, Monoclonal. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 15 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Acquired von Willebrand syndrome (AvWS) is a rare entity with approximately 700 cases described in the literature. A number of etiologies are responsible for this condition, mainly lymphoproliferative, myeloproliferative syndromes and cardiac diseases. Management is aimed at preventing and treating bleeds, as well as treating the underlying pathology. In the case of a monoclonal gammopathy, there are limited evidence and high heterogeneity only based on old case reports, resulting in poor quality recommendations. It seems essential in 2023 to take into account and offer the new anti-myeloma treatments available. Case Presentation: We describe the case of a patient with an AvWS secondary to an IgG smoldering multiple myeloma, experiencing multiple bleeding, treated successfully with daratumumab, lenalidomide, and dexamethasone, after multiple treatment failure.

Conclusion

Daratumumab, lenalidomide, and dexamethasone was demonstrated as a rapid and effective treatment for a patient with severe AvWS and multiple bleeding complications.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

LenalidomideDexamethasonevon Willebrand DiseasesAntibodies, MonoclonalSmoldering Multiple MyelomaAntineoplastic Combined Chemotherapy ProtocolsHumansMaleAgedFemale

Stichwörter der Autor:innen

Acquired von Willebrand syndromeAntimyeloma therapyDDAVPDaratumumabIntravenous immune globulinsSmoldering multiple myeloma

Substanzen

LenalidomidedaratumumabDexamethasoneAntibodies, Monoclonal

Autor:innen und Institutionen

  • Division of Haematology, Haemostasis and Thrombosis Unit, Saint-Luc University Hospital, Université catholique de Louvain (UCLouvain), Brussels, Belgium.
  • Division of Haematology, Arlon, Brussels, Belgium.

Zitieren

APA

Iarossi, M., Vekemans, M. M., Weynants, N., & Hermans, C. (2024). Acquired von Willebrand Syndrome Associated with a Smoldering Multiple Myeloma, Successfully Treated by Daratumumab, Lenalidomide, and Dexamethasone. Acta Haematologica. https://doi.org/10.1159/000536650

Vancouver

Iarossi M, Vekemans MM, Weynants N, Hermans C. Acquired von Willebrand Syndrome Associated with a Smoldering Multiple Myeloma, Successfully Treated by Daratumumab, Lenalidomide, and Dexamethasone. Acta Haematologica. 2024. doi:10.1159/000536650

BibTeX
@article{Iarossi2024,
  author = {Iarossi, Michael and Vekemans, Marie-Christiane Madeleine and Weynants, Nicolas and Hermans, Cedric},
  title = {Acquired von Willebrand Syndrome Associated with a Smoldering Multiple Myeloma, Successfully Treated by Daratumumab, Lenalidomide, and Dexamethasone},
  journal = {Acta Haematologica},
  year = {2024},
  doi = {10.1159/000536650}
}
Kostenlos starten →